NBY Novabay Pharmaceuticals Inc.
- 0 P/E
- 29.59 P/S
- 5.54 P/B
- -0.317 EPS
- -2,345.19% Cash ROIC
- 3.60 Cash Ratio
- 0 / 0% Dividend
- 129,960.00 Avg. Vol.
- 38.18M Shares
- 32.8M Market Cap.
NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
Ticker Report - Jan 30, 2015
The Wall Street Transcript - Jan 26, 2015
Seeking Alpha - Jan 7, 2015
NovaBay Pharma (NBY) Announces Strategic Realignment; May Spin Some non ... - StreetInsider.com (subscription)
GlobeNewswire (press release) - Mar 20, 2014
Seeking Alpha (registration) - Aug 20, 2014
GlobeNewswire (press release) - Nov 12, 2014
Seeking Alpha - Dec 9, 2013
GlobeNewswire (press release) - Jan 9, 2014
GlobeNewswire (press release) - Dec 2, 2013
Business Wire (press release) - Oct 27, 2014